Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.51 |
| ▸ | IL1B | P01584 | 10/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24840762 | 1.00 | NLRP3 (0.51) | NLRP3IL1BPOLBMAPK1NPSR1 | |
| SCHEMBL24840029 | 1.00 | NLRP3 (0.51) | NLRP3IL1BPOLBMAPK1NPSR1 | |
| SCHEMBL28934320 | 0.87 | NLRP3 (0.41) | NLRP3IL1BMAPK1 | |
| SCHEMBL28934321 | 0.87 | NLRP3 (0.41) | NLRP3IL1BMAPK1 | |
| SCHEMBL26772312 | 0.82 | NLRP3 (0.51) | NLRP3IL1B | |
| SCHEMBL30108895 | 0.81 | CHEK2 (0.45) | NLRP3IL1B | |
| SCHEMBL28934840 | 0.81 | CHEK2 (0.45) | NLRP3IL1B | |
| SCHEMBL28934843 | 0.81 | CHEK2 (0.45) | NLRP3IL1B | |
| SCHEMBL24840287 | 0.79 | NLRP3 (0.52) | NLRP3IL1B | |
| SCHEMBL28934400 | 0.79 | NLRP3 (0.52) | NLRP3IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4362946-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117881401-A | NLRP3 modulators | 祖玛珍生物科学有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023278438-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | NLRP3 1/4885IL1B 7/4885POLB 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.